^
    over1year
    Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=220, Suspended, Bellicum Pharmaceuticals | Recruiting --> Suspended
    Trial suspension • CAR T-Cell Therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification
    |
    Torisel (temsirolimus) • BPX-603
    over2years
    Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=220, Recruiting, Bellicum Pharmaceuticals | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion date • Trial primary completion date • CAR T-Cell Therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification
    |
    Torisel (temsirolimus) • BPX-603
    4years
    Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (clinicaltrials.gov)
    P1/2, N=220, Recruiting, Bellicum Pharmaceuticals
    Clinical • New P1/2 trial • CAR T-Cell Therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 overexpression • HER-2 amplification
    |
    Torisel (temsirolimus) • BPX-603